Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2664 - The inflamed immune phenotype can be induced by systemic treatment in angiogenic colorectal liver metastases in contrast to non-angiogenic liver metastases.

Date

09 Sep 2017

Session

Poster display session

Presenters

Stefan Stremitzer

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

S. Stremitzer1, P. Vermeulen2, M. Kockx3, L. Dirix4, S. Graver5, S. Scherer5, D. Yang6, W. Zhang7, J. Stift8, F. Wrba8, T. Gruenberger9, H. Lenz10

Author affiliations

  • 1 Department Of Surgery, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 2 Histogenex, Histogenex, Antwerp/BE
  • 3 Histogenex, Histogenex, 2600 - Antwerp/BE
  • 4 Department Of Medical Oncology, St-Augustinus Ziekenhuis, 2580 - Wilrijk/BE
  • 5 Biocenter Wuerzburg, University of Wuerzburg, Wuerzburg/DE
  • 6 Department Of Preventive Medicine, University of Southern California, Los Angeles/US
  • 7 Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
  • 8 Clinical Institute Of Pathology, Medical University Vienna, 1090 - Vienna/AT
  • 9 Department Of Surgery I, KA Rudolfstiftung - Krankenanstalt der Stadt Wien, 1030 - Vienna/AT
  • 10 Department Of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, 90033 - Los Angeles/US
More

Resources

Abstract 2664

Background

Recent data suggest that patients with colorectal cancer who present with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than patients who present with replacement (non-angiogenic) HGP CLM.

Methods

The immune phenotype (‘inflamed’, ‘excluded’, ‘desert’) was analyzed regarding the association with HGPs in a cohort of 118 patients with resectable CLM [m:f 66:52, median age 62.3 (31.0-80.4) years, median follow-up 32.2 (5.0-92.7) months] treated with 3 months of neoadjuvant and adjuvant bevacizumab-based chemotherapy and liver resection. The HGPs of CLM were assessed on H&E-stained sections according to international guidelines. The immune phenotypes were based on the distribution pattern of cytotoxic T-lymphocytes in CD8-immunostained tissue sections.

Results

In 39.8% of the lesions the predominant means of vascularization was vessel co-option, as reflected by the replacement HGP. This non-angiogenic growth was associated with worse recurrence-free and overall survival (RFS, OS) with hazard ratios (HR) of 2.03 and 2.63 (P = 0.002 and P = 0.005, respectively). The HGPs were associated with the immune phenotypes. About 60% of the desmoplastic (angiogenic) HGP CLM were ‘inflamed’, while this was true for only 17% of the replacement (non-angiogenic) HGP CLM. More than half of the CLM with non-angiogenic growth were characterized by an immune desert as opposed to only 6% of the angiogenic CLM (P 

Conclusions

Immune regulatory and angiogenesis pathways are known to interact. Our data suggest that the inflamed immune phenotype can be induced by systemic treatment in angiogenic CLM. The HGPs therefore are a potential biomarker for treatment that includes targeting the immune contexture.

Clinical trial identification

Legal entity responsible for the study

Heinz-Josef Lenz

Funding

NIH

Disclosure

H-J. Lenz: Consulting or advisory role: Bayer, Novartis, Merck KG, Genentech/Roche, Boehringer-Ingelheim. Research funding: EMD, Bayer, BMS, Genentech/Roche, Merck, Gilead, Medimmune, Array, BostonMedical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.